Teadusartiklid ja suulised ettekanded

Teadusartiklid

Uusküla A, Laisaar KT, Raag M, Lemsalu L, Lõhmus L, Rüütel K, Amico KR; HIV-BRIDGE Study Group.Effects of Counselling on Adherence to Antiretroviral Treatment Among People with HIV in Estonia: A Randomized Controlled Trial. AIDS Behav. 2017 Jul 17. doi: 10.1007/s10461-017-1859-6

Huik, K; Soodla, P; Rajasaar, H; Pauskar, M; Jõgeda, E; Kallas, E; Zilmer, K; Maimets, M; Kink, K; Semjonova, S; Kirs, K; Lutsar, I; Avi, R Virologic response to antiretroviral treatment in an Estonian HIV cohort study in 2015 (2017) 21th International Workshop on HIV Observational Databases

Lemsalu, L.; Rüütel, K.; Laisaar, KT.; Lõhmus, L.; Raidvee, A.; Uusküla, A.; HIV-BRIDGE Study Group (2017). Suicidal Behavior Among People Living with HIV (PLHIV) in Medical Care in Estonia and Factors Associated with Receiving Psychological Treatment. AIDS Behav, 21 (6), 1709−1716.10.1007/s10461-016-1561-0.

Huik, K; Soodla, P; Pauskar, M; Rajasaar, H; Jõgeda, E; Eveli, K; Avi, R; Lutsar, I The evaluation of two HIV-1 incidence assays in subjects infected with non-B subtype viruses. ECCMID2017

Laisaar, KT; Raag, M; Lemsalu, L; Lõhmus, L; Rüütel, K; Amico, K. R; Uusküla, A; and the HIV-BRIDGE Study Group (2017). Patient characteristics to consider when supporting antiretroviral therapy adherence in people living with HIV: a randomized controlled trial in Estonia. Conference Abstract Book: 12th International Conference on HIV Treatment and Prevention Adherence (ADHERENCE 2017); Miami, FL, USA: 04.-06.06.2017. International Association of Providers of AIDS Care (IAPAC), 84−84.

Laisaar, KT; Raag, M; Lutsar, I; Uusküla, A People living with HIV in Estonia: engagement in HIV care in 2013. Euro Surveill.2016Oct 27;21(43)

Kallas, E; Huik, K; Türk, S; Pauskar, M; Jõgeda, E; Šunina, M; Karki, T; Des Jarlais, D; Uusküla, A; Avi, R; Lutsar, I (2017). Differences in T cell distribution and CCR5 expression in HIV-positive and HIV-exposed seronegative persons who inject drugs. Medical microbiology and immunology, 205 (3), 231−239

Avi, R; Pauskar, M; Karki, T; Kallas, E; Jõgeda, E; Margus, T; Huik, K; Lutsar, I (2016). Prevalence of drug resistance mutations in HAART patients infected with HIV-1 CRF06_cpx in Estonia. Journal of Medical Virology, 88 (3), 448−454, 10.1002/jmv.24361.

Kallas, E; Huik, K; Türk, S; Pauskar, M; Jõgeda, E; Šunina, M; Karki, T; Des Jarlais, D; Uusküla, A; Avi, Radko; Lutsar, I (2016). T Cell Distribution in Relation to HIV/HBV/HCV Coinfections and Intravenous Drug Use. Viral immunology, 0−0.

Huik, K; Avi, R; Pauskar, M; Kallas, E; Jõgeda, E; Karki, T; Rüütel, K; Talu, A; Abel-Ollo, K; Uusküla, A; Carrillo, A; Ahuja, S; He, W; Lutsar, I (2016). A CCL5 Haplotype Is Associated with Low Seropositivity Rate of HCV Infection in People Who Inject Drugs. PloS one, 11 (6), e0156850−e0156850, 10.1371/journal.pone.0156850.

Jõgeda, E; Avi, R; Pauskar, M; Kallas, E; Karki, T; Des Jarlais, D; Uusküla, A; Lutsar, I; Huik, K (2016). Human T-lymphotropic virus types 1 and 2 are rare among intravenous drug users in Eastern Europe. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 43, 83−85, 10.1016/j.meegid.2016.05.022.

Kallas, E; Huik, K; Türk, S; Pauskar, M; Jõgeda, E; Šunina, M; Karki, T; Des Jarlais, D; Uusküla, A; Avi, R; Lutsar, I (2015). Differences in T cell distribution and CCR5 expression in HIV-positive and HIV-exposed seronegative persons who inject drugs. Medical microbiology and immunology, 1−9, 10.1007/s00430-015-0444-8.

Rhee, S.-Y.; Blanco, J.L.; Jordan, M.R.; Taylor, J.; Lemey, P.; Varghese, V.; Hamers, R.L.; Bertagnolio, S.; de Wit, T.F.R.; Aghokeng, A.F.; Albert, J.; Avi, R.; Avila-Rios, S.; Bessong, P.O.; Brooks, J.I.; Boucher, C.A.B.; Brumme, Z.L.; Busch, M.P.; Bussmann, H.; Chaix, M.-L.; Chin, B.S.; D’Aquin, T.T.; De Gascun, C.F.; Derache, A.; Descamps, D.; Deshpande, A.K.; Djoko, C.F.; Eshleman, S.H.; Fleury, H.; Frange, P.; Fujisaki, S.; Harrigan, P.R.; Hattori, J.; Holguin, A.; Hunt, G.M.; Ichimura, H.; Kaleebu, P.; Katzenstein, D.; Kiertiburanakul, S.; Kim, J.H.; Kim, S.S.; Li, Y.; Lutsar, I.; Morris, L.; Ndembi, N.; NG, K.P.; Paranjape, R.S.; Peeters, M.; Poljak, M.; Price, M.A.; Ragonnet-Cronin, M.L.; Reyes-Terán, G.; Rolland, M.; Sirivichayakul, S.; Smith, D.M.; Soares, M.A.; Soriano, V.V.; Ssemwanga, D.; Stanojevic, M.; Stefani, M.A.; Sugiura, W.; Sungkanuparph, S.; Tanuri, A.; Tee, K.K.; Truong, H.-H.M.; van de Vijver, D.A.M.C.; Vidal, N.; Yang, C.; Yang, R.; Yebra, G.; Ioannidis, J.P.A.; Vandamme, A.-M.; Shafer, R.W. (2015). Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis (PLoS Medicine). PLOS Medicine, 12(4), 1001810

 Soodla P, Rajasaar H, Avi R, Zilmer K, Kink K, Novikova L, Huik K, Maimets M, Lutsar I. Design and structure of the Estonian HIV Cohort Study (E-HIV).Infect Dis (Lond). 2015;47(11):768-75. doi: 10.3109/23744235.2015.1061203.

Kallas, E.; Huik, K.; Pauskar, M.; Jõgeda,E.-L.; Karki, T.; Des Jarlais, D.; Uusküla, A.; Avi, R.; Lutsar, I. (2015). Influence of interleukin 10 polymorphisms -592 and -1082 to the HIV, HBV and HCV serostatus among intravenous drug users. Infection, genetics and evolution, 30, 175 - 180.

Avi, R; Huik, K; Pauskar, M; Ustina, V; Karki,T; Kallas, E; Jõgeda, EL; Krispin, T; Lutsar, I (2014). Transmitted drug resistance is still low in newly diagnosed human immunodeficiency virus type 1 CRF06_cpx-infected patients in Estonia in 2010. AidsResearch and Human Retroviruses, 30(3), 278 - 283.

Huik, K.; Avi, R.; Uibopuu, H.; Pauskar, M.; Margus, T.; Karki, T.; Krispin, T.; Kool, P.; Rüütel, K.; Talu, A.; Abel-Ollo, K.; Uusküla, A.; Carrillo, AQ.; He, W.; Ahuja, SK.; Lutsar, I. (2014). Association between HIV-1 tropism and CCR5 human haplotype E in a Caucasian population. Jaids-Journal of Acquired Immune Deficiency Syndromes, 66(3), 239 - 244.

Huik, K; Avi, R; Pauskar, M; Kallas, E;Jõgeda, EL; Karki, T; Marsh, K; Des Jarlais, D; Uusküla, A; Lutsar, I (2013). Association between TLR3 rs3775291 and resistance to HIV among highly exposed Caucasian intravenous drug users. Infection,genetics and evolution, 20, 78 - 82.


Huik, K; Avi, R; Carrillo, A; Harper, N;Pauskar, M; Sadam, M; Karki, T; Krispin, T; He, W; Lutsar, I (2013). CCR5 Haplotypes Influence HCV Serostatus in Caucasian Intravenous Drug Users. PLoS ONE, 8(7), e70561


Lodi, S; del Amo, J; d'Arminio Monforte, A;Abgrall, S; Sabin, C; Morrison, C; Furrer, H; Muga, R; Porter, K; Girardi, E(2013). Risk of tuberculosis following HIV seroconversion in high-income countries. Thorax, 68(3), 207 -213.


Touloumi, G; Pantazis, N; Pillay, D;Paraskevis, D; Chaix, ML; Bucher, HC; Kucherer, C; Zangerle, R; Kran, AM;Porter, K (2013). Impact of HIV-1 subtype on CD4 count at HIV seroconversion, rate of decline, and viral load set point in European seroconverter cohorts. Clinical Infectious Diseases, 56(6), 888 -897.


Van der Helm, J; Geskus, R; Sabin, C; Meyer,L; Del Amo, J; Chene, G; Dorrucci, M; Muga, R; Porter, K; Prins, M (2013). Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after. Gastroenterology,144(4), 751 - 760.

Huang, X.; Lodi, S.; Fox, Z.; Li, W.; Phillips,A.; Porter, K.; Lutsar, I.; Kelleher, A.; Li, N.; Xu, X.; Wu, H.; Johnson, AM.(2012). Rate of CD4 decline and HIV-RNA change following HIV Seroconversion inmen who have sex with men: a comparison between the Beijing PRIMO and CASCADE cohorts. Jaids-Journal of Acquired Immune Deficiency Syndromes


Jarrin, I; Pantazis, N; Gill, MJ; Geskus, R;Perez-Hoyos, S; Meyer, L; Prins, M; Touloumi, G; Johnson, A; Hamouda, O; deOlalla, PG; Porter, K; del Amo, J (2012). Uptake of combination antiretroviral therapy and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia. Clinical Infectious Diseases, 54(1), 111 - 118.

 

Kaitstud doktoritööd

Kallas Eveli The influence of immunological markers to susceptibility to HIV, HBV, and HCV infections among persons who inject drugs (2017)

Kaja-Triin Laisaar  People living with HIV in Estonia: Engagement in medical care and methods of increasing adherence to antiretroviral therapy and safe sexual behavior (2016)

Kristi Huik The influence of host genetic factors on the susceptibility to HIV and HCV infections among intravenous drug users (2014)

Doktoritööd kirjutamisel

Kerstin Kase  The impact of CCR5 human haplotypes and co-infection with HCV on immune activation combination antiretroviral therapy in HlV-positive subjects (Inimese CCR5 haplotüüpide mõju immuunaktivatsioonile ja HIV ravi immunoloogilisele edukusele)

Ene-Ly Jõgeda The influence of HIV co-infections (HCV, HBV, GBV-C, HTLV) on chronic immune activation and its association with genotypes of HIV co-receptor CCR5. (HIV nakkusega kaasuvate viiruste (HCV, HBV, GBV-C, HTLV) mõju kroonilisele immuunaktivatsioonile ja selle seos HIV koretseptori CCR5 genotüüpidega)

Pilleriin Soodla Estimation of early HIV infection in Estonia (Varajase HIV infektsiooni leviku hindamine Eestis)

Suulised ettekanded

Kallas, E.; Avi, R.; Huik, K.; Türk, S.; Pauskar, M.; Jõgeda, E.-.L.; Šunina, M.; Des Jarlais, D.; Uusküla, A.; Lutsar, I. (2015). The distribution of TEMRA cells is influenced by HIV, HBV, HCV infections and intravenous drug use. 25th European Congress of Clinical Microbiology and Infectious Diseases; Copenhagen, Denmark, 25.-28. April 2015.

Pauskar, M; Avi, R.; Kallas, E.; Jõgeda, E-L.; Karki, T.; Uusküla, A.;  Des Jarlais, D; Lutsar, I.; Huik, K. Association between IL28B rs12979860 genotypes and susceptibility to HCV and/or HIV infection in Caucasian intravenous drug users. 25th European Congress of Clinical Microbiology and Infectious Diseases; Copenhagen, Denmark, 25.-28. April 2015.

Kase, K.; Rajasaar, H.; Avi, R.; Pauskar, M.; Zilmer, K.; Kink, K.; Novikova, L.;  Maimets, M.; Lutsar, I.; Huik, K. Co-infection with hepatitis C virus in Estonian HIV population during last two decades. 25th European Congress of Clinical Microbiology and Infectious Diseases; Copenhagen, Denmark, 25.-28. April 2015.

Soodla, P.; Rajasaar, H.; Maimets, M.; Lutsar, I. The Estonian HIV Cohort Study: Participant Characteristics Over Time. 25th European Congress of Clinical Microbiology and Infectious Diseases; Copenhagen, Denmark, 25.-28. April 2015.

Avi, R.; Huik, K.; Pauskar, M.; Kallas, E.; Jõgeda, E.-L.; Zilmer, K.; Ustina, V.; Novikova, L.; Karki, T.; Kisand, V.; Lutsar, I. (2014). Full-Length Genome Sequences of Estonian HIV-1 CRF06 and Eastern-European Subtype A1 Recombinant Forms. 7th National Congress HIV/AIDS and the 2nd Central European HIV Forum, Sibiu, Romania, 29-31 May 2014.

Jõgeda, E.-L.; Huik, K.; Avi, R; Pauskar, M., Kallas, E.; Karki, T.; Marsh, K.; Des Jarlais, D.; Uusküla, A.; Lutsar, I. (2014). Associations between MX2 polymorphism and the acquisition of HIV and co-infections in Caucasian intravenous drug users (IDUs). European Human Genetics Conference 2014, Milan, Italy, 31 May-3 June 2014.

Kallas, E.; Avi, R.; Huik, K.; Türk, S.; Pauskar, M.; Jõgeda, E.-.L.; Šunina, M.; Des Jarlais, D.; Uusküla, A.; Lutsar, I. (2014). Injection drug use influences T-cell distribution and CCR5 expression in HIV+ and ESN population. 24th European Congress of Clinical Microbiology and Infectious Diseases; Barcelona; 10-13 May 2014.

Kallas, E.; Huik, K.; Avi, R; Pauskar, M.; Jõgeda, E.-L.; Karki, T.; Marsh, K.; Des Jarlais, D.; Uusküla, A.; Lutsar, I. (2014). NLRP3 genotype CG increases the risk of HIV-1 in Caucasian intravenous drug users (IDUs). European Human Genetics Conference 2014, Milan, Italy, 31 May-3 June 2014.

Pauskar, M.; Huik, K.; Avi, R.; Kallas, E.; Jõgeda, E.-L.; Karki, T.; Semjonova, S.; Smidt, J.; Novikova, L.; Ainsalu, K.; Lutsar, I. (2014). Antiretroviral drug resistance and viral tropism in HIV-1 CRF06_cpx infected patients failing antiretroviral (ARV) therapy. 7th National Congress HIV/AIDS and the 2nd Central European HIV Forum, Sibiu, Romania, 29-31 May 2014.

Avi, R; Huik, K; Pauskar, M; Kallas, E; Jõgeda, EL; Karki, T; Šmidt, J; Novikova, L; Semjonova, S; Lutsar, I. (2013). Substitutions in RNaseH and Connection domain of HIV-1 CRF06_cpx viruses in treatment naive and treatment experienced populations. 11th European Meeting on HIV & Hepatitis- Treatment Strategies & Antiviral Drug Resistance; Rome; 20-22 March 2013, 35 - 35.

Jõgeda, EL; Huik, K; Pauskar, M; Kallas, E; Krispin, T; Karki, T; Marsh, K; Des Jarlais, D; Uusküla, A; Avi, R; Lutsar, I. (2013). The prevalence of GBV-C and its associations with HIV infection among Estonian intravenous drug users. In: Reviews in Antiviral Therapy Infectious Diseases: 11th European Meeting on HIV & Hepatitis- Treatment Strategies & Antiviral Drug Resistance; Rome; 20-22 March 2013, 46 - 47.

Kallas, E; Huik, K; Avi, R; Pauskar, M; Jõgeda, EL; Karki, T; Marsh, K; Des Jarlais, D; Uusküla, A; Lutsar, I (2013). The IL-10 promoter genotype AA at -592 is correlated with increased susceptibility to hepatitis B but not HIV infection in Caucasian intravenous drug users. European Human Genetics Conference 2013, Paris, France, 8.06.13-11.06.13.